BG Medicine (BG Medicine) Interest Expense : $-0.16 Mil (TTM As of Dec. 2015)

View and export this data going back to 2011. Start your Free Trial

What is BG Medicine Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. BG Medicine's interest expense for the three months ended in Dec. 2015 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2015 was $-0.16 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. BG Medicine's Operating Income for the three months ended in Dec. 2015 was $ -0.90 Mil. BG Medicine's Interest Expense for the three months ended in Dec. 2015 was $ 0.00 Mil. BG Medicine has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

BG Medicine Interest Expense Historical Data

The historical data trend for BG Medicine's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BG Medicine Interest Expense Chart

BG Medicine Annual Data

Trend

Dec05

Dec06

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Interest Expense

Get a 7-Day Free Trial

-0.09

-1.08

-1.17

-0.73

-0.16

BG Medicine Quarterly Data
	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15
Interest Expense	Get a 7-Day Free Trial															-0.13	-0.09	-0.06	-	-

BG Medicine Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.16 Mil.

BG Medicine (OTCPK:BGMD) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BG Medicine's Interest Expense for the three months ended in Dec. 2015 was $0.00 Mil. Its Operating Income for the three months ended in Dec. 2015 was $-0.90 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2015 was $0.00 Mil.

BG Medicine's Interest Coverage for the quarter that ended in Dec. 2015 is calculated as

BG Medicine had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

BG Medicine (BG Medicine) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BG Medicine Inc (OTCPK:BGMD) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

303 Wyman Street, Suite 300, Waltham, MA, USA, 02451

Website

http://www.bg-medicine.com

BG Medicine Inc manufacture and sell diagnostic products that are used to guide the patients suffering from heart failure and related disorders in the United States. It distributes its products such as BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme-linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.

Executives

Jeffrey R Luber	director	100 CAMPUS DRIVE, C/O EXACT SCIENCES CORP, MARLBOROUGH MA 01752
Noubar Afeyan	director, 10 percent owner	C/O FLAGSHIP PIONEERING, INC., 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Stelios Papadopoulos	director	3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020
Harry W Wilcox	director	ONE KENDALL SQ, BLDG 700, CAMBRIDGE MA 02139
Agtc Partners, L.p.	10 percent owner	C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142
Newcogen Group, Inc.	10 percent owner	C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142
Applied Genomic Technology Capital Fund Lp	10 percent owner	C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142
Flagship Pioneering Inc.	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Agtc Advisors Fund Lp	10 percent owner	ONE MEMORIAL DRIVE 7TH FLOOR CAMBRIDGE MA 02142
Kania Edwin M Jr	10 percent owner
Flagship Ventures Fund 2007, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Ventures 2007 General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Brian S Posner	director	14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Stephane Bancel	director	320 BENT STREET, CAMBRIDGE MA 02141
Harris Timothy J.r.	director	C/O BG MEDICINE, 610 LINCOLN STREET NORTH, WALTHAM MA 02451

BG Medicine (BG Medicine) Headlines

No Headlines